Clinical Trial Update: A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing E3810 at 10 mg once vs twice daily as maintenance therapy for PPI-resistant gastroesophageal reflux disease completed with posted result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• E3810

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Gastroesophageal Reflux Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-11-19